Protein degradation targeted chimera (PROTAC) PROTAC (PRO teolysis Targeting Chimera) is a technology that began 17 years ago (2001), using the intracellular “cleaner”, the ubiquitin-proteasome system (UPS). The normal physiological function […]
Read More →Preface Judging from the global drug sales trend in recent years, biological drugs have begun to become popular, while small molecular drugs are declining, and small molecular drug research and […]
Read More →Pre-diabetes is an increasingly common public health problem that has been recognized by international organizations such as the World Health Organization, the American Diabetes Association, and the International Diabetes Federation. […]
Read More →Concert Pharma recently released the final results of its recently completed phase II trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia […]
Read More →The development of inhibitors of Histone deacelytase (HDAC) is currently one of the hot spots, but the indications for the five drugs currently on the market are limited to the […]
Read More →Introduction The receptor for PD-L1 is PD-1, which belongs to the immunoglobulin superfamily and can bind to PD-L1 and PD-L2, respectively, and is their common receptor. PD-L1 is highly expressed […]
Read More →Recently, the third-generation EGFR inhibitor, Osimertinib (Tagrisso, AZD9291), was approved by the Chinese Food and Drug Administration (NMPA) for first-line treatment of patients with EGFR mutation-positive advanced or metastatic non-small […]
Read More →